Detailed Introduction

Product Name

Tirzepatide

Catalog Number

M21371

CAS Number

2023788-19-2

Formula

C225H348N48O68

Molecular Weight

4813.45

Solubility

DMSO 50 mg/mL

Storage

Powder -20°C 3 years ; 4°C 2 years

In solvent -80°C 6 months ; -20°C 1 month

Stability and Solubility Advice

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials and used within 1 month. Avoid repeated freeze and thaw cycles. Storage conditions for some special products should refer to their storage details

Compounded Tirzepatide is an injectable medication designed to assist with weight management, helping individuals reduce weight more effectively. It’s common to see impressive results with this cutting-edge, highly studied treatment. Clients using Tirzepatide have reported notable weight reductions, with some surpassing traditional benchmarks.

Tirzepatide is a novel medication that is used primarily for the treatment of type 2 diabetes and is being investigated for its potential benefits in weight management and obesity*treatment. It is a dual GIP (Gastric Inhibitory Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist, making it a unique and innovative therapy in the class of GLP-1 receptor agonists

1. Mechanism of Action,Tirzepatide works by activating two receptors: GIP and GLP-1.GLP-1 is a hormone that helps regulate blood sugar by stimulating insulin secretion, inhibiting glucagon (which raises blood sugar), and slowing gastric emptying.GIP also plays a role in insulin secretion and works in tandem with GLP-1 to enhance its effects.

By targeting both receptors, tirzepatide helps improve insulin sensitivity, regulate **blood glucose levels and promote weight loss in individuals with type 2 diabetes or obesity.

2. Indications

Type 2 Diabetes: Tirzepatide has been approved by the FDA for the treatment of type 2 diabetes to improve glycemic control in adults. It helps reduce HbA1c levels, a key indicator of blood sugar control over time.

Obesity and Weight Management: Clinical trials have shown that tirzepatide also leads to significant weight loss, making it a potential treatment for obesity. It is being explored as a weight-loss therapy for people with or without diabetes.

3. Clinical Efficacy

In clinical trials, tirzepatide has demonstrated superior efficacy compared to other medications in its class, such as semaglutide, in lowering HbA1c and promoting weight loss.

In studies like the SURPASS trials, tirzepatide showed significant reductions in HbA1c levels, ranging from 1.8% to 2.4%, and weight loss of up to 12-15% in patients with type 2 diabetes.

The weight loss seen with tirzepatide is often greater than that with traditional diabetes medications and is one of its major selling points.

4. Dosage and Administration

Tirzepatide is administered once a week via subcutaneous injection(under the skin).

The dosage typically starts low and can be gradually increased depending on the patient's response and tolerability.

The most common starting dose is 2.5 mg once weekly, with the possibility of increasing to 5 mg, 7.5 mg, or 10 mg as needed, based on individual patient needs.

5. Advantages Over Other Diabetes Medications

Tirzepatide offers several advantages over other diabetes treatments:

Dual receptor activation (GIP and GLP-1) provides more comprehensive metabolic control compared to single-receptor agents.

It has demonstrated superior efficacy in reducing blood sugar levels and promoting weight loss compared to other medications like GLP-1 agonists (e.g., semaglutide) and SGLT-2 inhibitors.

Its once-weekly dosing is convenient for patients who may struggle with daily medications.

Conclusion

Tirzepatide is a promising dual-action medication for managing type 2 diabetes and promoting weight loss. By targeting both the GLP-1 and GIP receptors, it offers significant improvements in glycemic control and weight management compared to traditional therapies. With its once-weekly injection and strong clinical results, tirzepatide represents an exciting advancement in the treatment of diabetes and obesity.